Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi & Co. Ltd.

www.shionogi.co.jp

Latest From Shionogi & Co. Ltd.

Asia Deal Watch: Qpex Partners Its Experimental Antibiotics With Brii In Greater China

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Deals Asia Pacific

Alzheimer’s Biomarker Benefit From Failed Janssen BACE Inhibitor?

New access agreement for samples from failed clinical trial to support identification of valuable new biomarkers, and possibly novel drugs, in highly challenging disorder.

Research & Development Neurology

Keeping Track: A Novel Approval For Fluorodopa F 18, A Tentative Approval For Vumerity, And A Missed Goal Date For Zilretta

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Cefiderocol Approval Likely After Panel Vote, But Future Still Clouded

Shionogi's cUTI drug clears US FDA advisory committee by 14-2, though a black box warning is possible after one of the clinical studies showed a potential mortality imbalance disfavoring cefiderocol in other diseases.

Advisory Committees Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Company Type
  • Top Japanese Pharma
  • Parent & Subsidiaries
  • Shionogi & Co. Ltd.
  • Senior Management
  • Isao Teshirogi, PhD, Pres. & CEO
  • Contact Info
  • Shionogi & Co. Ltd.
    Phone: (81) 6 6202 2161
    1-8, Doshomachi 3-chome
    Chuo-ku
    Osaka, 541 0045
    Japan
UsernamePublicRestriction

Register